A phase I dose-escalation trial with the new redox activated compound sodium trans-[tetrachlorobis(1 H-indazole)ruthenate(III)]/indazolhydrochloride (1:1.1) (FFC14A) in patients with solid tumors - a CESAR study

Autor:	M. E. Scheulen, B. Kynast, U. Jaehde, R. A. Hilger, E. Scheuch, V. Arion, P. Kupsch, M. M. Henke, C. Dittrich, B. K. Keppler
Rok vydání:	2004
Předmět:	Cancer Research Oncology
Zdroj:	Journal of Clinical Oncology. 22:2101-2101
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2004.22.90140.2101
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9c44fc0573e53635cb4a6b483047f1b2 https://doi.org/10.1200/jco.2004.22.90140.2101 Zobrazit plný text záznamu